Citadel Advisors
DNA icon

Citadel Advisors’s Ginkgo Bioworks DNA Stock Holding History

Citadel Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,114
Closed -$121K – 13010
2025
Q2 		$114K Buy
+10,114
New +$78.4K ﹤0.01% 11233
2025
Q1 		– Sell
-141,735
Closed -$1.44M – 14669
2024
Q4 		$1.39M Buy
+141,735
New +$1.21M ﹤0.01% 6375
2024
Q2 		– Sell
-113,226
Closed -$3.38M – 14452
2024
Q1 		$5.25M Buy
113,226
+42,852
+61% +$2.22M ﹤0.01% 3883
2023
Q4 		$4.76M Sell
70,374
-60,707
-46% -$3.72M ﹤0.01% 3868
2023
Q3 		$9.49M Buy
131,081
+105,249
+407% +$8.41M ﹤0.01% 2753
2023
Q2 		$1.92M Buy
25,832
+2,872
+13% +$170K ﹤0.01% 5215
2023
Q1 		$1.22M Buy
22,960
+19,891
+648% +$1.26M ﹤0.01% 6349
2022
Q4 		$207K Sell
3,069
-375
-11% -$34.5K ﹤0.01% 10068
2022
Q3 		$430K Sell
3,444
-59,596
-95% -$7.1M ﹤0.01% 8796
2022
Q2 		$6M Buy
63,040
+62,170
+7,146% +$7.58M ﹤0.01% 3475
2022
Q1 		$141K Sell
870
-15,413
-95% -$3M ﹤0.01% 11924
2021
Q4 		$5.41M Sell
16,283
-9,775
-38% -$4.64M ﹤0.01% 4155
2021
Q3 		$12M Buy
+26,058
New +$12.7M ﹤0.01% 2754

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's DNA Position: Q3 2025 in Review

Citadel Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2025, closing a stake of 10,114 shares — an estimated $121K sold.

Citadel Advisors first reported a position in DNA in Q3 2021 and held it in 13 quarters. The position peaked at $12M in Q3 2021. 173 funds tracked by Wall St. Rank hold DNA as of Q3 2025.

  • Citadel Advisors reported no remaining Ginkgo Bioworks position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 10,114 Ginkgo Bioworks shares in Q3 2025, an estimated $121K.
  • Citadel Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 13 quarters.
  • Citadel Advisors's Ginkgo Bioworks position peaked at $12M in Q3 2021.
  • 173 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.